Patents by Inventor Gernot Zissel

Gernot Zissel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER
    Publication number: 20210077577
    Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.
    Type: Application
    Filed: September 28, 2020
    Publication date: March 18, 2021
    Inventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse
  • Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease
    Patent number: 10786550
    Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: September 29, 2020
    Assignee: Universitatsklinikum Freiburg
    Inventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse
  • BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER
    Publication number: 20160354439
    Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.
    Type: Application
    Filed: May 6, 2016
    Publication date: December 8, 2016
    Inventors: Gernot ZISSEL, Joachim MÜLLER-QUERNHEIM, Antje Prasse
  • BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER
    Publication number: 20130109629
    Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse